Autoimmune thyroid disease correlates to islet autoimmunity on zinc transporter 8 autoantibody

in Endocrine Connections
View More View Less
  • 1 Y Cai, Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  • 2 J Yan, Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  • 3 Y Gu, Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  • 4 H Chen, Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  • 5 Y Chen, Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  • 6 X Xu, Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  • 7 M Zhang, Department of Endocrinology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, China
  • 8 L Yu, Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, United States
  • 9 X Zheng, Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  • 10 T Yang, Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Correspondence: Tao Yang, Email: yangt@njmu.edu.cn

Objective: The most common coexisting organ-specific autoimmune disease in patients with type 1 diabetes mellitus (T1DM) is autoimmune thyroid disease (AITD). However, there have been little clinical reports based on large population about the prevalence of zinc transporter 8 autoantibody (ZnT8A) and other islet autoantibodies in AITD patients. We aimed to explore the presence of islet autoantibodies, ZnT8A, glutamic acid decarboxylase autoantibodies (GADA) and insulinoma-associated antigen 2 autoantibodies (IA-2A) compared with thyroid autoantibodies, thyroid peroxidase autoantibodies (TPOAb) and thyroglobulin autoantibodies (TGAb) and thyrotropin receptor autoantibodies (TRAb) in patients with Graves’ disease (GD), Hashimoto’s thyroiditis (HT) and T1DM patients with AITD.

Methods: Totally, 389 patients with GD, 334 patients with HT, 108 T1DM patients with AITD and 115 healthy controls (HC) were recruited in the study. Islet autoantibodies (ZnT8A, GADA and IA-2A) were detected by radioligand binding assay. Thyroid autoantibodies, TPOAb and TGAb were detected by chemiluminescence assay, and TRAb was detected by radioimmunoassay.

Results: The prevalence of ZnT8A, GADA and IA-2A was higher in GD and HT patients than that of HC (ZnT8A: GD 8.48%, HT 10.8% vs HC 1.74%; GADA: GD 7.46%, HT 7.74% vs HC 0.870%; IA-2A: GD 4.88%, HT 3.59% vs HC 0%; All P<0.05); but lower than that of T1DM subjects with AITD (ZnT8A: 42.6%; IA-2A: 44.4%; GADA: 74.1%; all P<0.0001).

Conclusions: An increased prevalence of ZnT8A as well as GADA and IA-2A was found in both GD and HT patients, indicating that there is a potential link between thyroid autoimmunity and islet autoimmunity.

 

     European Society of Endocrinology

     Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 61 61 61
PDF Downloads 66 66 66